UBS raised the firm’s price target on Cigna (CI) to $375 from $340 and keeps a Buy rating on the shares. Cigna is clearing the overhang with its new PBM model, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target raised to $338 from $333 at TD Cowen
- Cigna: Regulatory Overhang Eases, Evernorth Growth Drives Renewed Buy Rating and Earnings Upside
- Cigna: Regulatory Overhangs Easing and PBM Model Transition Drive Clearer Profitability Outlook and Attractive Risk-Reward Supporting Buy Rating
- Cigna price target lowered to $303 from $305 at Barclays
- Cigna Earnings Call: Growth Holds Amid PBM Overhaul